10 completed, 6 terminated, 5 unknown, 1 withdrawn. 22 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 22 | Completed 10, Terminated 6, Unknown 5, Withdrawn 1 |
Follow Relapsing Remitting Multiple Sclerosis: new trials by email Literature Review of Relapsing Remitting Multiple Sclerosis trials Research Report on Relapsing Remitting Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis Personalized extended interval dosing of natalizumab, Standard interval dosing - Relapsing Remitting Multiple Sclerosis | Phase 4 | Unknown | Amsterdam UMC, location VUmc | 300 | 2020-02-03 | 2023-04-27 |
| Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis Fingolimod, Dimethyl Fumarate - Relapsing Remitting Multiple Sclerosis | Phase 4 | Terminated | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | 55 | 2017-04-30 | 2019-10-31 |
| Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy peginterferon beta-1a, interferon beta-1a, interferon beta-1b - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Biogen | 80 | 2017-01-30 | 2020-11-25 |
| Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis dimethyl fumarate, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 4 | Withdrawn | Biogen | 2015-07-01 | 2015-12-28 | |
| Fingolimod Effect on Cytokine and Chemokine Levels Fingolimod 0.5 mg - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 126 | 2015-03-31 | 2019-09-30 |
| Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 alemtuzumab GZ402673 - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Genzyme, a Sanofi Company | 1062 | 2015-01-07 | 2022-03-28 |
| Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation Simethicone, Loperamide, Peanut Butter - Relapsing Remitting Multiple Sclerosis | Phase 4 | Terminated | Rocky Mountain MS Research Group, LLC | 5 | 2014-07-01 | 2017-03-23 |
| Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya Fingolimod, Natalizumab - Relapsing Remitting Multiple Sclerosis | Phase 4 | Unknown | University Hospital Muenster | 15 | 2014-03-01 | 2014-12-25 |
| Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis Fingolimod - Relapsing Remitting Multiple Sclerosis | Phase 4 | Terminated | Heinrich-Heine University, Duesseldorf | 8 | 2013-01-01 | 2016-06-09 |
| Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. Fingolimod, Disease Modifying therapy - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 881 | 2012-06-08 | 2021-01-05 |
| Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) Fingolimod, Interferon beta - 1a (IFN), Glatiramer acetate (GA) - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 298 | 2012-01-01 | 2014-08-08 |
| Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy Fingolimod (FTY720) - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 347 | 2011-12-24 | 2019-01-25 |
| Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change Fingolimod, Standard MS DMT - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 61 | 2011-05-01 | 2015-06-22 |
| Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient vitamin A - Relapsing Remitting Multiple Sclerosis | Phase 4 | Unknown | Tehran University of Medical Sciences | 30 | 2011-04-01 | 2012-07-18 |
| Impact of Vitamin A on Multiple Sclerosis (MS) vitamin A, Drug: placebo - Relapsing Remitting Multiple Sclerosis | Phase 4 | Unknown | Tehran University of Medical Sciences | 100 | 2010-02-01 | 2011-08-16 |
| Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis Dietary Supplement: vitamin A, placebo - Relapsing Remitting Multiple Sclerosis | Phase 4 | Unknown | Tehran University of Medical Sciences | 20 | 2010-02-01 | 2012-10-12 |
| Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients Vitamin A, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Tehran University of Medical Sciences | 36 | 2009-10-01 | 2014-03-14 |
| How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose Interferon beta-1a - Relapsing Remitting Multiple Sclerosis | Phase 4 | Terminated | Biogen | 19 | 2007-06-01 | 2008-09-04 |
| Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate Glatiramer Acetate, Placebo, Prednisone - Relapsing Remitting Multiple Sclerosis | Phase 4 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 414 | 2005-01-01 | 2014-01-06 |
| Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS Glatiramer Acetate, Betaseron, Rebif - Relapsing Remitting Multiple Sclerosis | Phase 4 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 91 | 2004-07-01 | 2010-10-18 |
Showing 20 of 22. Sign in to see all of them.
Multiple Sclerosis, Relapsing-Remitting (22) · Multiple Sclerosis (10)
Autoimmune Diseases (22) · Autoimmune Diseases of the Nervous System (22) · Demyelinating Autoimmune Diseases, CNS (22) · Demyelinating Diseases (22) · Immune System Diseases (22) · Nervous System Diseases (22) · Multiple Sclerosis (12)
Fingolimod Hydrochloride (8) · Interferon beta-1a (7) · Glatiramer Acetate (4) · Interferon beta-1b (3) · Vitamin A (3) · Dimethyl Fumarate (2) · retinol palmitate (2) · Adrenal Cortex Hormones (1) · Loperamide (1) · Natalizumab (1) · Prednisone (1) · Simethicone (1) · peginterferon beta-1a (1)
Novartis Pharmaceuticals (5) · Biogen (4) · Tehran University of Medical Sciences (4) · Teva Branded Pharmaceutical Products R&D, Inc. (2) · Amsterdam UMC, location VUmc (1) · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta (1) · Genzyme, a Sanofi Company (1) · Heinrich-Heine University, Duesseldorf (1) · Merck KGaA, Darmstadt, Germany (1) · Rocky Mountain MS Research Group, LLC (1) · University Hospital Muenster (1)
Iran (4) · Australia (3) · Germany (3) · Italy (3) · United States (3) · Belgium (2) · Netherlands (2) · Russia (2) · Spain (2) · United Kingdom (2) · Argentina (1) · Brazil (1) · Canada (1) · Czechia (1) · Denmark (1)
Sama Bitarafan, MD, PhD student (2) · Ali Akbar Saboor Yaraghi, PhD (1) · Bernd Kieseier, Prof. (1) · Bettina Stubinski, M.D. (1) · Helene Brooks (1) · Jean-Louis Stril, MD (1) · John F Foley, MD (1) · Luisa Klotz, PD. Dr. med. (1) · Renato Mantegazza, MD (1) · Renato Turrini, MD (1)
PMID 21111490, PMID 23868508, PMID 26161708, PMID 26996107, PMID 30050529, PMID 31654272, PMID 31762387, PMID 32583052, PMID 32710396, PMID 33476880, PMID 34378446, PMID 34882037, PMID 37745914, PMID 37963723, PMID 39935588
2016 (1), 2017 (1)